In silico discovery of a perilipin 1 inhibitor to be used as a new treatment for obesity
M.H. Noureldein Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. m.hussein@pharma.asu.edu.eg
BACKGROUND: Obesity is a chronic non-communicable disease that affects a lot of people worldwide. Current management strategies for obesity include dietary management, physical exercises and pharmacological agents but sustenance of weight loss is still a problem. Perilipin 1 is a lipid droplet protein that is involved in lipolysis in adipose tissue. Perilipin 1 degradation or knock-out is associated with leanness.
AIM: The aim of this study is to use computational servers and software to predict the 3D structure of perilipin 1 and predict potential inhibitors to be used as treatment of obesity.
MATERIALS AND METHODS: The 3D structure of perilipin 1 was predicted by I-TASSER server. ZINC database was used to obtain potential inhibitors for perilipin 1. Docking of potential inhibitors was done using Molegro Virtual Docker.
RESULTS: The predicted 3D structure of perilipin 1 had a high confidence score reflecting the reliability of the obtained structure. 4-Nitrophenyl 2,3,4-Tri-O-levulinoyl-α-D-mannopyranoside showed a high reliable docking score suggesting its potential action as perilipin 1 inhibitor.
CONCLUSIONS: This study shows that 4-Nitrophenyl 2,3,4-Tri-O-levulinoyl-α-D-mannopyranoside can be used as an inhibitor for perilipin 1 and a potential treatment for obesity.
Free PDF Download![Creative Commons License](https://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
M.H. Noureldein
In silico discovery of a perilipin 1 inhibitor to be used as a new treatment for obesity
Eur Rev Med Pharmacol Sci
Year: 2014
Vol. 18 - N. 4
Pages: 457-460